Antibiotic treatment against methicillin-resistant staphylococcus aureus hospital-and ventilator-acquired Pneumonia: A step forward but the battle continues

Clinical Infectious Diseases

Volumn 54, Issue 5, 2012, Pages 630-632

  Torres, Antoni ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

LINEZOLID; TEICOPLANIN; VANCOMYCIN;

ANTIBIOTIC THERAPY; DIARRHEA; DRUG PENETRATION; GRAM POSITIVE COCCI; GRAM POSITIVE INFECTION; HEALTH CARE COST; HOSPITAL ACQUIRED PNEUMONIA; HUMAN; KIDNEY FAILURE; LEUKOPENIA; META ANALYSIS (TOPIC); METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MORBIDITY; MORTALITY; NEPHROTOXICITY; NOTE; POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY TRACT INFECTION; STAPHYLOCOCCUS INFECTION; UREMIA; VENTILATOR ASSOCIATED PNEUMONIA;

ACETAMIDES; ANTI-BACTERIAL AGENTS; CROSS INFECTION; FEMALE; HUMANS; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; OXAZOLIDINONES; PNEUMONIA, STAPHYLOCOCCAL;

EID: 84856822576     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cir907     Document Type: Note

References (22)

1. Chastre J, Fagon JY. Ventilator-associated pneumonia. Am J Respir Crit Care Med 2002; 165:867-903.
2. Rello J, Sa-Borges M, Correa H, et al. Variations in etiology of ventilator-associated pneumonia across four treatment sites: implications for antimicrobial prescribing practices. Am J Respir Crit Care Med 1999; 160:608-13.
3. Bodi M, Ardanuy C, Rello J. Impact of grampositive resistance on outcome of nosocomial pneumonia. Crit Care Med 2001; 29(Suppl 4): N82-6.
4. Cruciani M, Gatti G, Lazzarini L, et al. Penetration of vancomycin into human lung tissue. J Antimicrob Chemother 1996; 38:865-9.
5. Lamer C, de Beco V, Soler P, et al. Analysis of vancomycin entry into pulmonary lining fluid by bronchoalveolar lavage in critically ill patients. Antimicrob Agents Chemother 1993; 37:281-6.
6. Goetz MB, Sayers J. Nephrotoxicity of vancomycin and aminoglycoside therapy separately and in combination. J Antimicrob Chemother 1993; 32:325-34.
7. Rubinstein E, Cammarata S, Oliphant T, et al. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. Clin Infect Dis 2001; 32:402-12.
8. Wunderink RG, Cammarata SK, Oliphant TH, Kollef MH; Linezolid nosocomial pneumonia study group. Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia. Clin Ther 2003; 25:980-92.
9. Wunderink RG, Rello J, Cammarata SK, et al. Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 2003; 124:1789-97.
10. Kollef MH, Rello J, Cammarata SK, et al. Clinical cure and survival in gram-positive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin. Intensive Care Med 2004; 30:388-94.
11. Kalil AC, Murthy MH, Hermsen ED, et al. Linezolid versus vancomycin or teicoplanin for nosocomial pneumonia: a systematic review and meta-analysis. Crit Care Med 2010; 38:1802-8.
12. Walkey AJ, O'Donnell MR, Wiener RS. Linezolid vs glycopeptide antibiotics for the treatment of suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a meta-analysis of randomized controlled trials. Chest 2011; 139:1148-55.
13. Luna C, Didier B, Aruj P. Vancomycin, unbeatable for methicillin- resistant Staphylococcus aureus hospital-acquired pneumonia? Really? Crit Care Med 2010; 38:1910-2.
14. Wunderink RG, Niederman M, Kollef MH, et al. Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study. Clin Infect Dis 2011; 54:621-9.
15. Ewig S, Welte T, Chastre J, Torres A. Rethinking the concepts of community-acquired and health-care-associated pneumonia. Lancet Infect Dis 2010; 10:279-87.
16. Lodise TP, Patel N, Lomaestro BM, et al. Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. Clin Infect Dis 2009; 49:507-14.
17. Patel N, Pai MP, Rodvold KA, et al. Vancomycin: we can't get there from here. Clin Infect Dis 2011; 52:969-74.
18. Luna CM, Bruno DA, Garc?́a-Morato J, et al. Effect of linezolid compared with glycopeptides in methicillin-resistant Staphylococcus aureus severe pneumonia in piglets. Chest 2009; 135:1564-71.
19. Martinez-Olondris P, Rigol M, Soy D, et al. Efficacy of linezolid compared to vancomycin in an experimental model of pneumonia induced by methicillin-resistant Staphylococcus aureus in ventilated pigs. Crit Care Med 2011. [Epub ahead of print].
20. American Thoracic Society. Guidelines for the management of adults with hospitalacquired, ventilator-associated, and healthcareassociated pneumonia. Am J Respir Crit Care Med 2005; 171:388-416.
21. Haque NZ, Zuniga LC, Peyrani P, et al. Relationship of vancomycin minimum inhibitory concentration to mortality in patients with methicillin-resistant Staphylococcus aureus hospital-acquired, ventilator-associated, or health-care-associated pneumonia. Chest 2010; 138:1356-62.
22. Sánchez Garc?́a M, De la Torre MA, Morales G, et al. Clinical outbreak of linezolid-resistant Staphylococcus aureus in an intensive care unit. JAMA 2010; 303: 2260-4.